semaglutide flow trial kidney outcomes 2024 nejm hazard ratio Long-term of in obesity and cardiovascular disease in the SELECT Effects of semaglutide with and – Semaglutide in patients with overweight – Semaglutide reduces risk for major

McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE

Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia

Escalating Obesity Epidemic and Weight-Loss Approvals World Health Organization data confirm that worldwide obesity prevalence nearly tripled between 1975 and 2024, affecting more than 890 million adults

The main concerns with GLP-1 agonist drugs include: GI side effects (nausea, diarrhea, vomiting, constipation, abdominal pain) High out-of-pocket cost for those who do not quality under insurance Risk of inadequate nutrition (reduced intake + insufficient nutrition counseling) Significant loss of muscle mass & bone density High discontinuation rates (with lost weight regained) Limited public & clinician knowledge on importance/implementation of nutrition and lifestyle changes Side Effects and Costs of GLP-1 Medications The use of GLP-1 drugs has been associated with numerous side effects, ranging from mild to severe

This loss of muscle can lower your metabolic rate and make it harder to keep the weight off

Somatostatin Tone and Injection Timing Endogenous somatostatin is the brake on GH secretion